Patient case (clinical description): A 33-year-old woman comes to clinic complaining of progressive fatigue, decreased appetite, and 11-lb weight loss in the past 2 months.  She uses levothyroxine because of the previously diagnosed Hashimoto disease. She has no other medical conditions and does not use tobacco, alcohol, or illicit drugs.  Physical examination shows a generalized increase in pigmentation of the skin.  Measurement of serum cortisol before and after administration of exogenous adrenocorticotropic hormone (ACTH) shows no difference in the levels. Stable glucocorticoid replacement therapy starts for her with the diagnosis for primary adrenal insufficiency (Addison disease)

Patient's own account: I went to the clinic because I was really suffering from fatigue and decreased appetite and I also lost 11 pounds over the past two months. I'm just 33 years old so that's not normal, especially for a woman. I take levothyroxine because I have been diagnosed with Hashimoto disease. I don't have any other medical condition, and I don't smoke I don't drink, and I don't do drugs. They also did my physical examination and they saw that I had an increase in pigmentation of my skin. They measured my cortisol level before and after giving me some ACTH hormone, and the results came back with no difference whatsoever. The doctor told me I have Addison disease and put me under glucocorticoid therapy.

Clinical trial: Exercise Capacity and Recovery in Addison's Disease

Eligibility criteria:
Inclusion Criteria:

          -  Addison's disease

          -  18-50 years

          -  stable glucocortiocid replacement therapy

        Exclusion Criteria:

          -  Presence of intercurrent (acute) infectious disease

          -  Mental impairment (major depressive, anxiety, panic, adjustment, bipolar, psychotic,
             posttraumatic or borderline personality disorder)

          -  Presence of the following chronic diseases: diabetes mellitus, chronic obstructive
             pulmonary disease, renal failure, chronic anaemia, malignancy, rheumatoid arthritis

          -  Presence of the following cardiovascular conditions: unstable angina pectoris, history
             of myocardial infarction, uncontrolled cardiac arrhythmias causing symptoms or
             hemodynamic compromise, symptomatic (severe) aortic stenosis, uncontrolled symptomatic
             heart failure, acute myocarditis or pericarditis, left main coronary stenosis,
             moderate stenotic valvular heart disease, tachyarrhythmias or bradyarrhythmias,
             hypertrophic cardiomyopathy and other forms of outflow tract obstruction, high-degree
             atrioventricular block

          -  History of pulmonary embolus or pulmonary infarction

          -  Known aortic aneurysm

          -  Severe hypertension (>170/100 mm Hg)

          -  Medication that affects cardiovascular function (beta-blocker, calcium antagonist,
             ACE-inhibitors, aldosterone-antagonists)
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 50 Years

Eligibility (NLI label): Entailment